SHR-2524
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 12, 2026
Jiangsu Hengrui Pharmaceuticals…announced NMPA clearance to initiate a Phase I clinical trial evaluating SHR-2524 injection in combination with bevacizumab as first-line treatment for advanced hepatocellular carcinoma (HCC)
(flcube.com)
New P1 trial • Hepatocellular Cancer
1 to 1
Of
1
Go to page
1